[1]张耀庭 李烽 朱永翔 陆丽洁 龙明智.沙库巴曲/缬沙坦在室性心律失常中的研究进展[J].心血管病学进展,2019,(7):982-984.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.004]
　ZHANG Yaoting,LI Feng,ZHU Yongxiang,et al.Research Progress of Sacubitril/Valsartan in Ventricular Arrhythmia[J].Advances in Cardiovascular Diseases,2019,(7):982-984.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.004]
点击复制

沙库巴曲/缬沙坦在室性心律失常中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年7期
页码:
982-984
栏目:
综述
出版日期:
2019-10-25

文章信息/Info

Title:
Research Progress of Sacubitril/Valsartan in Ventricular Arrhythmia
作者:
张耀庭1; 2 李烽1; 2 朱永翔1; 2 陆丽洁1; 2 龙明智2
龙明智2 (1. 南京医科大学,江苏 南京 211166 ;2. 南京医科大学第二附属医院心血管内科,江苏 南京 210011 )
Author(s):
ZHANG Yaoting1; 2;  LI Feng1; 2;  ZHU Yongxiang1; 2;  LU Lijie1; 2;  LONG Mingzhi2
(1. Nanjing Medical University, Nanjing 211166, Jiangsu, China; 2. Department of Cardiology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, China)
关键词:
沙库巴曲/缬沙坦; 室性心律失常; 心源性猝死
Keywords:
Sacubitril/Valsartan;  Ventricular arrhythmia;  Sudden cardiac death
DOI:
10.16806/j.cnki.issn.1004-3934.2019.07.004
摘要:
沙库巴曲/缬沙坦作为新型的抗心力衰竭药物，也是首个血管紧张素受体-脑啡肽酶抑制剂。有研究显示其能降低心力衰竭患者心源性猝死及死亡的风险。现对沙库巴曲/缬沙坦的简介、作用机制及与室性心律失常的关系等做一综述。
Abstract:
As a new anti-heart failure drug, sacubitril/valsartan is the first angiotensin receptor-neprilysin inhibitor. Studies have shown that it reduces the risk of sudden cardiac death in patients with heart failure. This article reviews the introduction, mechanisms and relationship with ventricular arrhythmia of sacubitril/valsartan

参考文献/References:

[1] Landstrom AP, Dobrev D, Xht W. Calcium signaling and cardiac arrhythmias[J]. Circ Res,2017,120(12):1969-1993.

[2] Shen L,Jhund PS, Petrie MC,et al. Declining risk of sudden death in heart failure[J]. N Engl J Med,2017,377(1): 41-51.

[3] 刘滔,徐俊波,吴镜. 沙库巴曲缬沙坦治疗心力衰竭的新进展[J]. 心血管病学进展,2018,39(3):483-486.

[4] Desai AS,Mcmurray JJ,Packer M,et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients[J]. Eur Heart J,2015,36(30):1990-1997.

[5] Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs[J]. Nat Rev Cardiol,2017,14(3):171-186.

[6] Mullens W,Martens P. Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure[J]. JACC Heart Fail,2018,6(6):S2213177918302178.

[7] Campbell DJ. Neprilysin inhibitors and bradykinin[J]. Front Med (Lausanne),2018,5:257.

[8] Kario K. The sacubitril/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in hypertension, heart failure, and beyond[J]. Curr Cardiol Rep,2018,20(1):5.

[9] Ryan JW, Berryer P, Chung AY, et al. Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin[J]. J Pharmacol Exp Ther,1994,269(3):941-947.

[10] Piedimonte G,Nadel JA,Long CS, et al. Neutral endopeptidase in the heart. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation[J]. Circ Res,1994,75(4):770-779.

[11] Sarrias A,Bayes-Genis A. Is sacubitril/valsartan (also) an antiarrhythmic drug[J]. Circulation,2018,138(6):551-553.

[12] Curcio A, Torella D, Iaconetti C, et al. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts[J]. PLoS One,2013,8(7):e70158.

[13] de Diego C,González-Torres L,Nú?ez JM,et al. Effects of angiotensin-neprilysin inhibition as compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices[J]. Heart Rhythm,2018,15(3):395-402.

[14] Martens P,Nuyens D,Rivero-Ayerza M,et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol,2019,Feb 20. DOI: 10.1007/s00392-019-01440-y[Epub ahead of print].

[15] Vicent L,Juárez M,Martín I,et al. Ventricular arrhythmic storm after initiating sacubitril/valsartan[J]. Cardiology,2018,139(2):119.

[16] Algra A,Tijssen JG,Roelandt JR,et al. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death[J]. Br Heart J,1993,70(1):43-48.

[17] Langenickel TH,Jordaan P,Petruck J,et al. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization[J]. Eur J Clin Pharmacol,2016,72(8):917-924.

相似文献/References:

[1]王双 冯景辉 吴丽馨 付俊博 吴秀萍.脑啡肽酶抑制剂对心力衰竭患者认知功能的研究进展[J].心血管病学进展,2019,(9):1253.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.017]
　WANG ShuangFENG JinghuiWU LixinFU JunboWU Xiuping.Enkephalase Lnhibitors on Cognitive Function in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(7):1253.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.017]
[2]梁砚薷李晶洁.神经元型钠通道在室性心律失常发生机制中的作用[J].心血管病学进展,2020,(1):43.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.012]
　LIANG Yanru,LI Jingjie.Role of Neuronal Sodium Channels in Development of Ventricular Arrhythmias[J].Advances in Cardiovascular Diseases,2020,(7):43.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.012]
[3]刘磊 杨震.心肌梗死后左心室壁瘤相关室性心律失常的形成机制与治疗进展[J].心血管病学进展,2020,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.013]
　LIU Lei,YANG Zhen.Mechanism and Progress in Treatment of Post-infarction Left Ventricular Aneurysm with Ventricular Arrhythmias[J].Advances in Cardiovascular Diseases,2020,(7):46.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.013]
[4]罗功名 彭瑜 张钲.碎裂QRS波群对急性心肌梗死的诊断和预后预测价值的研究进展[J].心血管病学进展,2020,(6):579.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.005]
　LUO GongmingPENG YuZHANG Zheng.Fragmented QRS Complex in the Diagnostic and Prognosis Value of Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(7):579.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.005]
[5]赵若寒 罗素新 熊峰 李袁静 黄龙祥.心力衰竭并发复杂性室性心律失常相关因素分析[J].心血管病学进展,2020,(7):782.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.025]
　ZHAO Ruohan,LUO Suxin,XIONG Feng,et al.Analysis of Related Factors of Heart Failure Accompany?span style="">with Complex Ventricular Arrythmia[J].Advances in Cardiovascular Diseases,2020,(7):782.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.025]
[6]杨超,文颐 崔凯军.左室穹顶部起源室性心律失常消融治疗进展[J].心血管病学进展,2021,(2):106.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.003]
　YANG ChaoWEN YiCUI Kaijun.Ablation of Ventricular Arrhythmia Originating from Left Ventricular Summit[J].Advances in Cardiovascular Diseases,2021,(7):106.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.003]
[7]王思博 王连生.心肌梗死后室性心律失常的治疗进展[J].心血管病学进展,2021,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
　WANG SiboWANG Liansheng.Treatment of Ventricular Arrhythmias after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(7):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
[8]董震宇 商鲁翔 汤宝鹏.立体定向放射治疗在心律失常中的应用进展[J].心血管病学进展,2022,(2):97.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.001]
　DONG ZhenyuSHANG LuxiangTANG Baopeng.Application progress of Stereotactic Body Radiation Therapy in Arrhythmia[J].Advances in Cardiovascular Diseases,2022,(7):97.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.001]
[9]王秀秀 熊峰.左心室假腱索的再认识[J].心血管病学进展,2023,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.016]
　WANG Xiuxiu,XIONG Feng.Re-Recognition of Left Ventricular False Tendon[J].Advances in Cardiovascular Diseases,2023,(7):67.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.016]
[10]素比努尔·吾布力卡斯木 李耀东.肾去交感神经术治疗植入型心律转复除颤器植入术后电风暴的研究进展[J].心血管病学进展,2023,(3):208.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.004]
　Subinuer·Wubulikasimu,LI Yaodong.Renal Sympathetic Denervation in Treatment of Electrical Storm After Implantable Cardioverter Defibrillator Implantation[J].Advances in Cardiovascular Diseases,2023,(7):208.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.004]

更新日期/Last Update: 2019-12-16